A5005349974- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Genomics and Rare Diseases
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Genomics and Phylogenetic Studies
- Cytokine Signaling Pathways and Interactions
- Immune cells in cancer
- Molecular Biology Techniques and Applications
- Immune Response and Inflammation
Hartwig Medical Foundation
2019-2024
University of Amsterdam
2019
Whole genome sequencing (WGS) using fresh-frozen tissue and matched blood samples from cancer patients may become the most complete genetic tumor test. With increasing availability of small biopsies need to screen more number biomarkers, use a single all-inclusive test is preferable over multiple consecutive assays. To meet high-quality diagnostics standards, we optimized clinically validated WGS sample data processing procedures, resulting in technical success rate 95.6% for with sufficient...
Abstract The current increase in number and diversity of targeted anticancer agents poses challenges to the logistics timeliness molecular diagnostics (MolDx), resulting underdiagnosis treatment. Whole‐genome sequencing (WGS) may provide a sustainable solution for addressing as well future diagnostic challenges. present study therefore aimed prospectively assess feasibility, validity, value WGS routine clinical practice. was conducted independently of, parallel with, standard care (SOC) on...
Abstract Background ‘Precision oncology’ can ensure the best suitable treatment at right time by tailoring towards individual patient and comprehensive tumour characteristics. In current molecular pathology, diagnostic tests which are part of standard care (SOC) only cover a limited spectrum genomic changes, often performed in an iterative way. This occurs expense valuable time, available tissue sample, interferes with ‘first right’ decisions. Whole Genome Sequencing (WGS) captures near...
The host immune response is characterized by a complex interplay of signal-specific cellular transcriptional responses. magnitude the dependent on strength external stimulus. Knowledge leukocyte responses altered in to different stimulus dosages man lacking. Here, we sought identify signatures LPS dose humans. Healthy human volunteers were administered 1 ng/kg (n = 7), 2 6), or 4 7) intravenously. Blood was collected before (pre-LPS) and h after administration. Total RNA analyzed microarrays...
Abstract Whole genome sequencing (WGS) using fresh frozen tissue and matched blood samples from cancer patients is becoming in reach as the most complete genetic tumor test. With a trend towards availability of small biopsies need to screen an increasing number (complex) biomarkers, use single all-inclusive test preferred over multiple consecutive assays. To meet high-quality diagnostics standards, we optimized clinically validated WGS sample data processing procedures resulting technical...
In current practice, determining patients' eligibility for a clinical study is typically 'study-orientated'. Frequently, however, candidate patient ineligible due to negative result of the (companion) biomarker test. Often, there insufficient time or tissue available reconsider and test an alternative study. The increase in biomarker-driven trials, together with availability clinical-grade comprehensive testing, warrants more screening strategy by which all options are elucidated...
3013 Background: In the next few years numerous drugs will be approved for defined genomic targets, most of these in a tumor agnostic manner. Identifying patients who can benefit from this is critical future success precision medicine, ideally using single comprehensive test to detect all possible biomarkers. The WIDE study (WGS Implementation standard cancer Diagnostics Every patient) aimed evaluate feasibility, clinical validity (primary endpoints) and added value (secondary endpoint)...